Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
$0.01
$1.99
$278K-0.91.77 million shs147,446 shs
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$0.30
$0.58
$0.18
$16.00
$10.94M0.84822,537 shs309,164 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.14
$1.22
$8.45
$45.46M1.5329,344 shsN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$0.70
$2.53
$0.67
$5.95
$28.88M2.521.12 million shs417,901 shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$15.24
-2.2%
$16.40
$11.83
$23.81
$1.23B0.4496,440 shs244,005 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
-4.26%+12.50%-30.77%-82.76%-99.44%
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
0.00%0.00%0.00%0.00%-16.78%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%-99.99%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
+0.09%-0.62%-2.66%-76.99%-65.93%
Verona Pharma plc stock logo
VRNA
Verona Pharma
-2.25%-7.07%-2.99%-14.77%-32.54%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/AN/AN/AN/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.8414 of 5 stars
4.13.00.00.00.02.51.3
Verona Pharma plc stock logo
VRNA
Verona Pharma
1.003 of 5 stars
3.50.00.00.01.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
2.00
HoldN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.25
Hold$5.67707.45% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.00
Buy$33.60120.47% Upside

Current Analyst Ratings

Latest FREQ, SPRB, VRNA, NBRV, and ATHX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Verona Pharma plc stock logo
VRNA
Verona Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.00
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $3.00
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$9.00 ➝ $2.00
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$9.00 ➝ $2.00
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/14/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
3/5/2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
3/4/2024
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
3/1/2024
Verona Pharma plc stock logo
VRNA
Verona Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athersys, Inc. stock logo
ATHX
Athersys
$146K1.90N/AN/A($1.33) per share0.00
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$14.07M0.78N/AN/A$1.96 per share0.15
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$10.09M2.86N/AN/A$1.88 per share0.37
Verona Pharma plc stock logo
VRNA
Verona Pharma
$460K2,677.60N/AN/A$3.10 per share4.92

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/A-223.03%N/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$47.92M-$1.25N/AN/AN/A-474.96%-52.31%-39.77%5/20/2024 (Estimated)
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/14/2024 (Estimated)

Latest FREQ, SPRB, VRNA, NBRV, and ATHX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/13/2024Q4 2023
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$0.41-$0.23+$0.18-$0.23$1.65 million$2.89 million
2/29/2024Q4 2023
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.23-$0.16+$0.07-$0.16N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/A
5.81
5.81
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.02
4.18
4.18
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.20
33.33
33.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
13.18%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
4636.52 million30.39 millionNot Optionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
3932.02 million31.49 millionNot Optionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2941.15 million37.41 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
7980.82 million76.94 millionOptionable

FREQ, SPRB, VRNA, NBRV, and ATHX Headlines

SourceHeadline
Verona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper SandlerVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandler
americanbankingnews.com - April 17 at 3:36 AM
Verona Pharma (NASDAQ:VRNA) Trading 3.7% Higher  After Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgrade
americanbankingnews.com - April 17 at 1:08 AM
Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade
marketbeat.com - April 16 at 10:36 AM
Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper SandlerVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler
marketbeat.com - April 16 at 8:33 AM
Verona Pharma (NASDAQ:VRNA) Shares Up 4.9%Verona Pharma (NASDAQ:VRNA) Shares Up 4.9%
marketbeat.com - April 4 at 3:08 PM
American Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)American Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - March 28 at 4:07 AM
VRNA Apr 2024 17.500 callVRNA Apr 2024 17.500 call
finance.yahoo.com - March 16 at 8:32 AM
VRNA Apr 2024 15.000 callVRNA Apr 2024 15.000 call
finance.yahoo.com - March 16 at 3:31 AM
Andrew Fisher Joins Verona Pharma as General CounselAndrew Fisher Joins Verona Pharma as General Counsel
globenewswire.com - March 4 at 2:00 AM
Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D PipelineBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline
markets.businessinsider.com - March 1 at 1:10 PM
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call TranscriptVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 1:10 PM
3 Healthcare Stocks That Have Outperformed Nvidia Since 20223 Healthcare Stocks That Have Outperformed Nvidia Since 2022
fool.com - March 1 at 8:45 AM
Verona Pharma plc 2023 Q4 - Results - Earnings Call PresentationVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 29 at 11:18 AM
Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - February 29 at 10:48 AM
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial ResultsVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
finance.yahoo.com - February 29 at 10:48 AM
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - February 29 at 2:00 AM
Verona Pharma earnings preview: what to expectVerona Pharma earnings preview: what to expect
markets.businessinsider.com - February 28 at 1:35 PM
When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?
finance.yahoo.com - February 25 at 12:52 PM
Verona Pharma PLC ADRVerona Pharma PLC ADR
wsj.com - February 25 at 7:52 AM
VRNA Mar 2024 15.000 putVRNA Mar 2024 15.000 put
finance.yahoo.com - February 17 at 7:46 PM
VRNA Jun 2024 30.000 callVRNA Jun 2024 30.000 call
finance.yahoo.com - February 17 at 2:46 PM
Verona Pharma: A Few Points From The Bull And Bear CaseVerona Pharma: A Few Points From The Bull And Bear Case
seekingalpha.com - February 15 at 5:55 PM
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
finance.yahoo.com - February 15 at 10:20 AM
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
globenewswire.com - February 15 at 2:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Athersys logo

Athersys

NASDAQ:ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
Frequency Therapeutics logo

Frequency Therapeutics

NASDAQ:FREQ
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Nabriva Therapeutics logo

Nabriva Therapeutics

NASDAQ:NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Spruce Biosciences logo

Spruce Biosciences

NASDAQ:SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Verona Pharma logo

Verona Pharma

NASDAQ:VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.